February 8th, 2012: Today in Canadian Tech

Mad Catz Interactive today reported its Q3, 2012 results. Sales of $46.2-million compared unfavorably with last year's Q3 sales of $93 million, which was a record for the company.

Absolute Software (TSX:ABT) reported its Q2, 2012 results. Revenue was $18.4 million vs. $16.8 million for the same period last year. John Livingston, Absolute’s CEO said “”Our dedication to delivering market-leading solutions for tracking, managing and securing end-point devices is translating into solid financial results.” Shares of Absolute closed up 3.3% to $4.70. Full Story

Mad Catz Interactive (TSX:MCZ) reported its Q3, 2012 results. Sales were $46.2-million compared with last year’s Q3 sales of $93 million, which was a record. Mad Catz President and CEO Darren Richardson said: “The decline in financial results for the fiscal 2012 third quarter largely reflects the difficult year-ago comparison which benefited significantly from strong sales of products related to specific video games and strong revenue from a third party distribution agreement, which has since been discontinued.” Shares of Mad Catz closed up 4.8% to $.66. Full Story

_________________________________________________________________________________________________________________________

This story is brought to you by Verisante (TSX:VRS). The Canadian Cancer Society named Verisante Core a Top 10 Cancer Breakthrough of 2011. Click here for more information.

Bioniche Life Sciences (TSX:BNC) reported its Q2, 2012 results. Revenues came in at $8.1-million, compared with $11 million in the same period last year. Bioniche President and CEO Graeme McRae said “We are pleased to see the increase in sales revenues related to our animal health products in the second quarter as compared to the same period last year, as well as on a year-to-date basis.” Shares of Bioniche closed up 2.3% to $.90 cents. Full Story

Calian Technologies (TSX:CTY) released its Q1, 2012 results. Revenues for the quarter were $56.8-million, a 7% increase from the $53.3-million reported in the same quarter last year. Calian President and CEO Ray Basler said “Today, we reported the highest level of first quarter revenues and earnings in the company’s history, and we are very pleased to start the fiscal year on such a strong note.” The company also declared a quarterly dividend of 26 cents per share, payable March 7, 2012, to shareholders of record as of Feb. 22, 2012. Shares of Calian closed up 2.7% to $18.85. Full Story

Critical Outcome Technologies (TSXV:COT) announced it had engaged Montreal’s Algorithme Pharma to develop and validate the final quantitative method to be used for preclinical and phase 1 studies for COTI-2. Critical Outcome President and CEO Dr. Wayne Danter said “”The development and validation of a bioanalytical method for COTI-2 in human plasma represents another important milestone in the preparation of COTI-2 for its first in human study,” Shares of Critical Outcome closed even at $.15 cents. Full Story

Functional Technologies (TSXV:FEB) submitted a Generally Recognized as Safe (GRAS) notification to the FDA for the company’s acrylamide-preventing (AP) yeast. Howard Louie, Functional Technologies’ executive chairman and chief business development officer said “The submission of our GRAS notification to the FDA for our proprietary acrylamide-preventing yeast, as well as any other regulatory applications we may make in the future, are fundamental to Functional Technologies’ demonstration of its commitment towards ensuring safety and quality of the products we have or intend to release to the market.” Shares of Functional Technologies closed today even at $.42 cents. Full Story

_________________________________________________________________________________________________________________________